Stereotactic Body Radiation Therapy as a Derivative of Stereotactic Radiosurgery: Clinically Independent but with Enduring Common Themes

The document discussed the development and application of stereotactic body radiation therapy (SBRT) as an evolution of stereotactic radiosurgery (SRS), emphasizing its effectiveness in treating various cancers such as non-small-cell lung cancer, prostate, pancreatic, and hepatocellular cancer. SBRT achieved high local control and survival rates, with a 5-year biochemical relapse-free survival rate of 93% in prostate cancer patients and a 3-year local control rate of 91% in hepatocellular cancer patients. It was noted for its cost-effectiveness and minimal interruption of chemotherapy in pancreatic cancer. Despite its benefits, concerns about genitourinary toxicity and limitations of traditional radiobiological models were highlighted. The document concluded that while SBRT and SRS shared technological roots, they had distinct clinical applications and potential for further advancement.